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Dear Editor,
Multiple acyl-CoA dehydrogenase deficiency (MADD; OMIM# 
231680) is an autosomal recessive fatty acid oxidation disorder 
[1]. Through the expanded newborn screening test (NST), its 
prevalence has been estimated to be 1 in 750,000–2,000,000 
newborns [2]. MADD is divided into three clinical types [3]: the 
neonatal onset form with (type I) or without (type II) congenital 
anomalies [4], and the late-onset form (type III), which is often 
asymptomatic [5]. MADD is caused by defects in electron trans-
fer flavoprotein (ETF) or electron transfer flavoprotein ubiqui-
none oxidoreductase (ETFDH) [6, 7]. Approximately 300 pa-
tients worldwide have been diagnosed as having MADD by ge-
netic analysis, and 100 ETFDH mutations have been reported 
to date [8]. We report two MADD patients carrying novel, likely 
pathogenic variants, in ETFDH for the first time in Korea. Writ-
ten informed consent was obtained from the patients’ parents.
Patient 1 was a newborn boy who was transferred to the neo-
natal intensive care unit of our hospital on the sixth day of life, 
following onset of hypotonia, metabolic acidosis, hyperammone-
mia, and hypoglycemia 24 hours after birth. He was born full-
term with a weight of 3,650 g (50–90th percentile) to healthy, 
non-consanguineous parents. An older brother had died on the 
third day of birth due to undetermined causes. An older sister 
was typically developing and, thus far, without illness.
At the referring hospital, intravenous hydration with multivita-
mins was administered for a week with supplementation of L-
carnitine (300 mg/kg/day) and carglumic acid (100 mg/kg/day), 
but metabolic acidosis showed no improvement. When he first 
arrived at the hospital, he showed mild tachypnea and his ante-
rior fontanel was large, but normotensive. He was hypotonic 
with an absent Moro reflex. A severe “sweaty feet” odor was 
noted. Laboratory tests revealed hyperammonemia (153 μg/dL; 
normal range, 15–51 μg/dL) and metabolic acidosis (pH, 7.250; 
HCO3-, 15.1 mmol/L) without hypoglycemia. Tiny renal cysts 
were detected by ultrasonography, and hypoplastic bilateral 
temporal opercula were noticed on brain magnetic resonance 
images. Biventricular hypertrophy with normal contractility func-
tion was observed by echocardiography.
Acylcarnitine profiling by tandem mass spectrometry (TMS) 
and urine organic acid analysis suggested MADD type I (Table 
1). A high dose of riboflavin (100 mg/day) was started immedi-
ately after obtaining the abnormal metabolic results, with a low-
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fat diet and L-carnitine supplementation (300 mg/kg/day). The 
ammonia level was nearly normal after continuous intravenous 
infusion of sodium benzoate (250 mg/kg/day), and the patient 
showed slightly increased muscle tone. However, metabolic aci-
dosis persisted, and elevated C-reactive protein with decreased 
urine and distended abdomen implied the progress of sepsis. 
Antibiotics and an antifungal agent were administered to treat 
peritonitis and cellulitis on the abdominal wall. Respiratory sup-
port was needed due to pulmonary edema. Even with antibiotics 
and inotropes, the patient died of sepsis with multiple organ fail-
ure 38 days after birth (Table 1).
Patient 2 was a boy born full-term with a weight of 3,480 g 
(10–50th percentile) to healthy, non-consanguineous parents. 
He had no symptoms at birth, but NST by TMS on the third day 
after birth showed elevated plasma acylcarnitines, suggesting 
MADD. Plasma acylcarnitine profile normalized on repeated 
Table 1. Biochemical and genetic data of two male Korean patients with multiple acyl-CoA dehydrogenase deficiency 
No. Case Subtype
Age at 
diagnosis
Plasma acylcarnitine 
(μmol/L)
Urine organic acid 
(mmol/mol Cr)
Gene
Genetic alteration 
[zygosity]
ACMG 
category
1 Neonatal-onset with 
congenital 
anomalies (type I)
12 days C4 9.95 (cutoff, 0.80)
C5 12.66 (cutoff, 0.40)
Glutarate 4223.55 (cutoff, <3.0)
Ethylmalonate 709.49 (cutoff, <6.5)
2-Hydroxyglutaric acid 273.33 (cutoff, <69.5)
Methyl-succinate 194.74 (cutoff, not detected)
Adipic acid 118.41 (cutoff, <32.0)
Isovalerylglycine 63.70 (cutoff, not detected)
Fumarate 122.23 (cutoff, <14.0)
ETFDH p.Arg452Gly [Het]
deletions exons 7–8 [Het]
LP
P
2 Late-onset (type III) 7 days C6 0.24 (cutoff, 0.18)
C8 0.62 (cutoff, 0.39)
C10 0.63 (cutoff, 0.3) 
Ethylmalonate 39.81 (cutoff, <14.6)
Adipic acid 46.71 (cutoff, <34.3)
Suberic acid 35.54 (cutoff, <10.1)
Sebacic acid 23.96 (cutoff, <1.4)
ETFDH c.831+3A>C [Het]
deletions exons 1–7 [Het]
LP
P
Abbreviations: Het, heterozygote; LP, likely pathogenic; P, pathogenic; ACMG, American College of Medical Genetics and Genomics.
Fig. 1. Family pedigrees of two male Korean patients with multiple acyl-CoA dehydrogenase deficiency, carrying recessively inherited 
ETFDH variants. (A) Patient 1. (B) Patient 2. Affected and unaffected individuals are indicated by closed and open symbols, respectively. 
ETFDH alleles are represented by ‘[=]’ (wild-type), ‘p.Arg452Gly (c.1354A>G)’, ‘c.831+3A>C’. Exon deletions and mutant alleles were 
identified by quantitative PCR and Sanger sequencing, respectively.
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testing, but urine glutarate increased slightly. Monitoring of urine 
organic acids after 8 hours of fasting by TMS revealed mildly el-
evated blood C6, C8, and C10, and increased urinary metabo-
lites (Table 1). Based on these findings, a low-fat diet supple-
mented with medium-chain triglyceride milk, L-carnitine (100 
mg/kg/day), and riboflavin (100 mg/day) was initiated at the age 
of four months.
Following treatment initiation, plasma acylcarnitines normal-
ized, and urinary ethylmalonate decreased. The patient is cur-
rently 24 months old. He has normal height (50–75th percen-
tile) and weight (25–50th percentile), and is achieving normal 
developmental milestones.
For genetic diagnosis, we first sequenced ETFA, ETFB, and 
ETFDH, and identified one variant of ETFDH in each patient: 
c.1354A>G (p.Arg452Gly) for Patient 1 and c.831+3A>C for 
Patient 2 (Table 1). We investigated the other allele using quan-
titative (q)PCR to identify exon deletions. We used genomic 
DNA from two normal infants as controls, and qPCR was run in 
triplicate using 13 primer pairs for each exon. Data were ana-
lyzed by the 2–ΔΔCt method [9], and mean values are presented. 
Patient 1 had exon 7–8 deletion, and Patient 2 had multiple de-
letions in exons 1–7 (Fig. 1). Both parents of each patient were 
heterozygous carriers of each variant detected in their offspring; 
they were molecularly confirmed as compound heterozygotes 
with c.1354A>G (p.Arg452Gly) and exon 7–8 deletion for Pa-
tient 1, and with c.831+3A>C and exon 1–7 deletion for Patient 
2. The two sequence variants were absent from population da-
tabases, located in highly conserved regions, and considered 
damaging to protein function or structure by in-silico prediction. 
The variants were in trans with the other exon deletions in each 
patient as indicated by parental analyses. Therefore, p.Arg-
452Gly and c.831+3A>C could be classified as likely patho-
genic according to the 2015 American College of Medical Ge-
netics and Genomics standards/guidelines [10] (Fig. 1). 
Early diagnosis and immediate treatment during the neonatal 
period determines the outcome in MADD. Expanded NST has 
increased the detection rate; however, accurate diagnosis may 
not be achieved with biochemical profiling alone. Thus, genetic 
analysis is likely necessary for either confirmative diagnosis or 
exclusion.
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